ATLANTA, GA – – (Newsfile Corp. – December 2, 2021) – – Holzer & Holzer, LLC is investigating whether BeyondSpring, Inc. (“BeyondSpring” or the “Company”) (NASDAQ: BYSI) complied with federal securities laws. On December 1, 2021, BeyondSpring announced that it received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) for the Company’s New Drug Application (“NDA”) and that in the CRL the FDA indicated it cannot approve the Company’s NDA in its current form. On this news, the Company’s stock dropped. If you purchased BeyondSpring stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Provide Your Information To Take Action

  • Date PurchasedNumber of Shares AcquiredAcquisition Price Per Share 
  • Date SoldNumber of Shares SoldSelling Price Per Share 
  • Signed pursuant to the Uniform Electronic Transactions act as adopted by the various states and territories of the United States.

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt